Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Central nervous system (CNS) inflammatory and cytokine pathways encompass the coordinated signaling networks and cellular activities that drive immune responses within the brain and spinal cord. These pathways are primarily mediated by resident glial cells, including microglia and astrocytes, which respond to pathological insults by secreting a variety of cytokines such as Tumor necrosis factor-alpha (TNF-alpha), Interleukin-1 beta (IL-1 beta), and Interleukin-6 (IL-6) (DiSabato et al., 2016, J Neurochem). While transient activation of these pathways is essential for tissue repair and defense against pathogens, chronic or dysregulated neuroinflammation is a central driver of neuronal damage in neurodegenerative disorders like Alzheimer's disease, Parkinson's disease, and Multiple sclerosis (Glass et al., 2010, Cell). Pharmacological intervention typically targets specific nodes within these pathways, such as cytokine receptors or intracellular signaling kinases, to mitigate the neurotoxic effects of sustained inflammation (Becher et al., 2017, Immunity). However, therapeutic development is challenged by the dual role of many cytokines in both neuroprotection and neurodegeneration, as well as the difficulty of achieving effective drug delivery across the blood-brain barrier (Mamik & Power, 2017, J NeuroVirol).
Modulation of neuroinflammatory responses through the antagonism of pro-inflammatory cytokine receptors, neutralization of circulating cytokines (e.g., Tumor necrosis factor-alpha, Interleukin-1 beta), inhibition of glial cell activation, and restriction of peripheral immune cell infiltration across the blood-brain barrier (Tansey et al., 2022, Nat Rev Immunol).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Central nervous system inflammatory and cytokine pathways (CNS inflammatory pathways).